Literature DB >> 34142340

Circular RNA circHIPK3 modulates prostate cancer progression via targeting miR-448/MTDH signaling.

D C Liu1, L L Song2, X Z Li1, Q Liang1, Z G Zhang1, C H Han3.   

Abstract

PURPOSE: Prostate cancer (PCa) is one of the most diagnosed cancers in men worldwide. Several studies have identified that circular RNAs (circRNAs) have a crucial impact on the biological processes in PCa. Therefore, it is necessary to study the molecular mechanism of circRNAs in tumor progression and metastasis.
METHODS: RNA interference was used to decrease circHIPK3 and MTDH expression. Overexpression vector was used to increase circHIPK3 and MTDH expression. Luciferase reporter assay were used to detect the relationship between circHIPK3 and miR-448 or between miR-448 and MTDH. MTT assay, colony formation assay and transwell assay were used to measure proliferation and migration of PCa cells.
RESULTS: Circular RNA circHIPK3 was significantly increased in PCa tissues and cell lines. And overexpression of circHIPK3 promoted the migration, proliferation, and invasion of PC-3 and 22Rv1 cells, while knockdown of circHIPK3 markedly repressed the above-mentioned series of biological processes. Furthermore, circHIPK3 promoted metadherin (MTDH) expression by sponging miR-448. In vivo experiments, it was also found that overexpression of circHIPK3 significantly promoted tumor growth.
CONCLUSIONS: Our research shows that circHIPK3 plays a carcinogenic effect in PCa by regulating the miR-448/MTDH axis, indicating that circHIPK3 may be a potential therapeutic target for PCa.
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  CircHIPK3; MTDH; MiR-448; Prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 34142340     DOI: 10.1007/s12094-021-02650-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

1.  [Molecular-targeted therapy for prostate cancer].

Authors:  Hideaki Miyake; Masato Fujisawa
Journal:  Nihon Rinsho       Date:  2016-01

2.  MiR-448 downregulates CTTN to inhibit cell proliferation and promote apoptosis in glioma.

Authors:  H-Y Su; Z-Y Lin; W-C Peng; F Guan; G-T Zhu; B-B Mao; B Dai; H Huang; Z-Q Hu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-06       Impact factor: 3.507

3.  CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer.

Authors:  N Liu; J Zhang; L-Y Zhang; L Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-06       Impact factor: 3.507

4.  MicroRNA‑30a‑5p suppresses tumor cell proliferation of human renal cancer via the MTDH/PTEN/AKT pathway.

Authors:  Jianmin Li; Changying Li; Hongjie Li; Ting Zhang; Xiaodong Hao; Jiwu Chang; Yong Xu
Journal:  Int J Mol Med       Date:  2017-11-17       Impact factor: 4.101

5.  MiR-182-5p inhibited proliferation and metastasis of colorectal cancer by targeting MTDH.

Authors:  Y Jin; Z-L Zhang; Y Huang; K-N Zhang; B Xiong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-02       Impact factor: 3.507

6.  Upregulation of circHIPK3 promotes the progression of gastric cancer via Wnt/β-catenin pathway and indicates a poor prognosis.

Authors:  W-G Liu; Q Xu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-09       Impact factor: 3.507

7.  Silencing the expression of MTDH increases the radiation sensitivity of SKOV3 ovarian cancer cells and reduces their proliferation and metastasis.

Authors:  Jun Chen; Yan Jia; Zan-Hui Jia; Yu Zhu; Yue-Mei Jin
Journal:  Int J Oncol       Date:  2018-08-28       Impact factor: 5.650

8.  [Circular RNA CircHIPK3 Promotes NCI-H1299 and NCI-H2170 Cell Proliferation through miR-379 and its Target IGF1].

Authors:  Fang Tian; Yun Wang; Zhe Xiao; Xuejun Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-07-20
  8 in total
  1 in total

1.  circHIPK3 regulates cell proliferation and migration by sponging microRNA-124 and regulating serine/threonine kinase 3 expression in esophageal squamous cell carcinoma.

Authors:  Da Yao; Shengcheng Lin; Size Chen; Zhe Wang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.